Mindwalk Holdings Corp (HYFT) Stock Price, Quote & News

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 620 4187

Website: www.mindwalkai.com

Address:

Industrious 823 Congress Ave, Suite 300, Austin, United States

LouiseVutton Feb. 6 at 7:45 AM

$HYFT

0 · Reply

chucky1110 Feb. 6 at 7:05 AM

$HYFT Want the CEO out? Want to know what's involved in getting it done? Ask ChatGPT, Grok and Claude. Claude gives solid answers! Hint - yes, it is possible, not easy!

0 · Reply

Homerun416 Feb. 6 at 3:23 AM

$HYFT worth $65M..constant missteps by management got us here. Nothing else. Could be 500$M + if they could execute as they constantly promise.

1 · Reply

local42r Feb. 5 at 11:08 PM

$HYFT Sure glad I sold @ 2.60 But I'm still sniffing around. It looks like a pig and smells like a pig.

0 · Reply

NyseDayTrader Feb. 5 at 9:09 PM

$HYFT People probably thought I was dramatic yelling to fire bath for over a year since I came back in. I witnessed first hand in 2021, when the stock was free falling from double digits, she was posting on social media about her son’s high school basketball accomplishments like a typical house mom without a care in the world.

0 · Reply

Uncle_Salty Feb. 5 at 8:48 PM

$HYFT Amost NO institutional support, NO insider's buying in ages. Hey CEO Bath, hows that buying back 5% of shares working out for increasing sharholder 'value' ??? 🤨

0 · Reply

Scam_Likely Feb. 5 at 8:38 PM

$HYFT Time to throw the Bath out with the baby water. New YTD low.

1 · Reply

PrimePorter Feb. 5 at 7:45 PM

$HYFT

0 · Reply

iambaron Feb. 5 at 6:03 PM

$HYFT So I was told they are dropping PRs during times before the European market opens because they are getting more activity with European traders… Meanwhile it looks like they are dumping the ATM here for the past two weeks. Lots of 10k-25k shares constantly hitting the bids. Sometimes 40k. At this point any sellers would be out. Seems they don’t care about their US investors here. Fumbled the influenza news and caused a sell off. Now diluting into low volume with no catalyst causes the downward bleed. Wish companies would understand a bit better how and when to dilute as well as releasing during normal hours. Texas based company? We should be releasing during US market hours.

1 · Reply

NyseDayTrader Feb. 5 at 5:44 PM

$HYFT Consolidating here tells me the swing traders that were looking for the deal during JPM are mainly out. We should settle back in the $1.70-$1.90 range until further advancements. P.S get rid of Jennifer Bath!!!!

2 · Reply

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

Jan 14, 2026, 8:00 AM EST - 22 days ago

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Jan 12, 2026, 7:00 AM EST - 24 days ago

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 9, 2026, 8:01 PM EST - 27 days ago

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Dec 15, 2025, 1:29 PM EST - 7 weeks ago

MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

Dec 15, 2025, 8:30 AM EST - 7 weeks ago

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

Dec 8, 2025, 8:30 AM EST - 2 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

Nov 13, 2025, 9:00 AM EST - 3 months ago

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Oct 21, 2025, 8:28 AM EDT - 3 months ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 17, 2025, 8:18 AM EDT - 3 months ago

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Oct 15, 2025, 7:00 AM EDT - 4 months ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 9, 2025, 2:26 PM EDT - 4 months ago

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

Oct 9, 2025, 7:00 AM EDT - 4 months ago

MindWalk Announces Share Repurchase Program

Sep 22, 2025, 7:02 AM EDT - 4 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 15, 2025, 12:58 PM EDT - 5 months ago

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

Sep 15, 2025, 8:44 AM EDT - 5 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 3, 2025, 8:48 AM EDT - 5 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 2, 2025, 8:01 AM EDT - 5 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Aug 27, 2025, 8:22 AM EDT - 5 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 6, 2025, 8:00 AM EDT - 6 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 6 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Jul 29, 2025, 12:39 PM EDT - 6 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 8:28 AM EDT - 6 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 24, 2025, 8:22 AM EDT - 7 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 21, 2025, 8:28 AM EDT - 7 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 16, 2025, 8:05 AM EDT - 7 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 14, 2025, 8:01 AM EDT - 7 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 7, 2025, 9:00 AM EDT - 7 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 3, 2025, 8:19 AM EDT - 7 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jun 24, 2025, 7:02 AM EDT - 8 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 12, 2025, 8:01 AM EDT - 8 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 5, 2025, 8:01 AM EDT - 8 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

May 21, 2025, 8:49 AM EDT - 9 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 20, 2025, 8:28 AM EDT - 9 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 12, 2025, 8:01 AM EDT - 9 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

Apr 11, 2025, 8:40 AM EDT - 10 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Mar 28, 2025, 12:59 PM EDT - 11 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 8:01 AM EDT - 11 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 13, 2025, 7:02 AM EDT - 11 months ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 11, 2025, 10:17 PM EDT - 11 months ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 5, 2025, 8:01 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Feb 26, 2025, 8:01 AM EST - 1 year ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 24, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 20, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Jan 27, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 22, 2025, 7:02 AM EST - 1 year ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 17, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Dec 31, 2024, 7:56 PM EST - 1 year ago

IPA Announces Resignation of Chief Financial Officer

Dec 30, 2024, 10:03 PM EST - 1 year ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

Dec 23, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

LouiseVutton Feb. 6 at 7:45 AM

$HYFT

0 · Reply

chucky1110 Feb. 6 at 7:05 AM

$HYFT Want the CEO out? Want to know what's involved in getting it done? Ask ChatGPT, Grok and Claude. Claude gives solid answers! Hint - yes, it is possible, not easy!

0 · Reply

Homerun416 Feb. 6 at 3:23 AM

$HYFT worth $65M..constant missteps by management got us here. Nothing else. Could be 500$M + if they could execute as they constantly promise.

1 · Reply

local42r Feb. 5 at 11:08 PM

$HYFT Sure glad I sold @ 2.60 But I'm still sniffing around. It looks like a pig and smells like a pig.

0 · Reply

NyseDayTrader Feb. 5 at 9:09 PM

0 · Reply

Uncle_Salty Feb. 5 at 8:48 PM

$HYFT Amost NO institutional support, NO insider's buying in ages. Hey CEO Bath, hows that buying back 5% of shares working out for increasing sharholder 'value' ??? 🤨

0 · Reply

Scam_Likely Feb. 5 at 8:38 PM

$HYFT Time to throw the Bath out with the baby water. New YTD low.

1 · Reply

PrimePorter Feb. 5 at 7:45 PM

$HYFT

0 · Reply

iambaron Feb. 5 at 6:03 PM

1 · Reply

NyseDayTrader Feb. 5 at 5:44 PM

2 · Reply

NyseDayTrader Feb. 5 at 4:41 PM

$HYFT To note. Nothing has changed with Mindwalks technology, in fact it only has advanced. My only issue has been with Jennifer bath and her lack of leadership in advancing this impressive technology and rightfully so, with her track record from 2018. Futures bright...

0 · Reply

canuck_trader92 Feb. 5 at 4:23 PM

$HYFT Buying the dip!

0 · Reply

NyseDayTrader Feb. 5 at 2:40 PM

$HYFT it looks like the seller the past week was fabricating the price premarket, and today it wasn’t. let’s hope he was cleaned up yesterday

0 · Reply

Twills08 Feb. 5 at 11:34 AM

$HYFT Add catalyst and stir. The company has a lot going for it. Dropped after retail profit taking. I’m here and not going anywhere. I like what I see. They need a large investor to start the ball rolling. Once that happens, I expect big things.

0 · Reply